With new technologies considered the biggest contributors to rising healthcare costs, stakeholders want the federal government to ramp up funding even further in the wake of a spate of new programs.

AI has tremendous potential, but researchers wanted to know what might happen if they turned all that power against the clinicians they are supposed to be helping.

With the exploratory paper, the FDA takes another step toward catching up with the pace of machine learning innovation.

The excitement around any new technology comes with a side order of fears about how that system or service will affect people, and, even in healthcare, AI is no exception.

Anthem Blue Cross and Stanford University hope to lead the way in using artificial intelligence to tackle price transparency and other healthcare concerns.

When it comes to evaluating AI, says one expert, we should recognize that there are still many questions to ask about how AI can best operate so that it properly augments medical professionals without adversely impacting overall public health.

Specific strengths of AI, says one platform developer, can be a very good match in filling in some of human nature's organic gaps and, by extension, helping doctors provide safer, more thorough treatment to their patients.

According to officials, the sprint “allowed for an open exchange of ideas and the opportunity for further collaboration between the U.S. government and private sector companies.” 

The new Center for Clinical Artificial Intelligence will develop new advances and applications for AI and machine learning in healthcare.